T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Bristol Myers Squibb hasn’t had much luck with its efforts to develop cancer treatments called T cell engagers. But the pharmaceutical company isn’t done pursuing this type of targeted cancer therapy, ...

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...